Clinicopathologic factors and MTV were analyzed for their association with locoregional control (LRC) and overall survival (OS).
introduction
The prognosis for squamous cell carcinoma of the larynx and hypopharynx remains poor because about 40% of patients present with locoregionally advanced disease at the time of diagnosis [1] . Accurate prediction of the response to treatment and the overall prognosis are important in selecting the optimal treatment strategy. Clinical tumor-node-metastasis (TNM) stage determined by the clinical and radiogical extent of the tumor has been utilized in deciding on the course of treatments and in prognosticating in head and neck cancer patients. Many additional clinicopathologic or biological markers have been investigated to predict outcomes and supplement the TNM stage [2] [3] [4] [5] . 18 F-FDG PET/CT measurement of tumor glucose metabolism as a marker of tumor metabolic activity is valuable in diagnosing head and neck squamous cell carcinoma (HNSCC) patients, in deciding on the best treatment course and in predicting the outcome [6] [7] [8] [9] . High tumor 18 F-FDG uptake is associated with high tumor viability and proliferative activity and a less favorable outcome [9] . The maximum standardized uptake value (SUV max ) is currently the most commonly used parameter in 18 F-FDG PET/CT. However, the SUV max only shows the highest intensity of 18 F-FDG uptake, as measured by the highest pixels within a region of interest, and cannot reflect the metabolic activity of the whole tumor.
Metabolic tumor volume (MTV), an unproven 18 F-FDG PET/CT parameter, is a volumetric measurement of tumor cells with increased 18 F-FDG uptake. Previous studies have calculated the tumor volume by CT or MRI [10, 11] . The MTV on 18 F-FDG PET/CT image not only measures tumor volume but also shows the metabolic activity, which helps predict the therapeutic response and prognosis of patients with HNSCC. In this study, we evaluated the prognostic value of MTV in patients with locoregionally advanced laryngeal and hypopharyngeal cancer.
materials and methods

patient population
We reviewed the records of 146 patients with newly diagnosed advanced-stage laryngeal or hypopharyngeal cancer, who had been treated at Asan Medical Center from January 2004 to September 2009. The principal eligibility criteria included histologically proven squamous cell carcinoma of the larynx or hypopharynx at clinical stage III or IV without distant metastasis. Sixty-five patients were excluded because of different pathologic diagnoses, history of previous treatments, inadequate clinical data or their MTV could not be calculated from 18 F-FDG PET/ CT data. The remaining 81 patients formed the cohort for this study. The distributions of age, sex, site of primary tumor, TNM stage, histologic grade, primary treatment strategy, and follow-up duration of the study population are provided in Table 1 . This study was conducted under the review and approval of the Institutional Review Board of our institution.
treatments
The treatment modalities for the patients were discussed at a multidisciplinary team meeting consisting of the surgical, medical, and radiation oncologists. The patients were divided by primary treatment strategy: the 47 patients in the surgery group underwent curative surgery with or without adjuvant therapy and the 34 patients in the non-surgery group received radiotherapy (RT) with or without chemotherapy. Patients in the surgery group underwent total or partial laryngectomy with or without pharyngectomy and had radical (n = 4), modified radical (n = 19), or selective (n = 23) neck dissection, with 33 having bilateral dissection. Four patients received induction chemotherapy and 34 patients received postoperative RT (median dose, 59.4 Gy; range, 7.7-70.0 Gy) using single daily fractions. Two patients also received postoperative chemotherapy. Indications for postoperative adjuvant therapy relied on the postoperative pathologic findings such as status of resection margin, local invasiveness, cervical lymph node involvement, and extracapsular spread of tumor. Of the 34 patients in the non-surgery group, 25 received chemoradiation therapy (CRT) and 9 received RT alone. RT consisting of intensitymodulated or three-dimensional conformal radiation was administered in daily fractions of 1.8 or 2.0 Gy for 5 days per week for 8 weeks. The median radiation dose for all patients was 70.0 Gy (range 60.0-73.8 Gy). CRT consisted of high-dose cisplatin (80-100 mg/m 2 ) infused on days 1, F-FDG. Spiral CT images were acquired with 110 mAs, 120 kVp (current-time product), from thigh to head, followed by a threedimensional craniocaudal PET scan. PET images were reconstructed with corrections for attenuation using CT data, and reoriented into axial, sagittal, and coronal slices. 18 F-FDG PET/CT findings were reviewed on the workstation by nuclear medicine physicians who identified visible lesions with increased tracer uptake and quantified their 18 F-FDG uptake. The SUV max was analyzed according to the equation SUV = A/(ID/BW), where A is the decaycorrected activity in tissue (in mCi per ml), ID is the injected dose of FDG (in mCi), and BW is the patient's body weight (in grams).
MTVs were computed from attenuation-corrected PET data using a commercial software package (INFINITT PACS; INFINITT Healthcare Co. Ltd). 18 F-FDG PET data were read into the workstation in DICOM format and intensity values were automatically converted to SUVs. For MTV calculation, the contouring margins around the tumor were defined using a fixed SUV of 2.5, which was validated in several previous studies [13] [14] [15] . Using a graphical user interface, a region of interest was drawn to enclose the whole hypermetabolic tumor lesion on each axial, coronal, and sagittal slice. The tumor volume was then delineated with the SUV 2.5 isocontour. The software program automatically calculated the volume of tumor within each region of interest. The total metabolic volume of each tumor and neck node was then summated (Figure 1 ).
statistical analysis
Locoregional control (LRC) rate and overall survival (OS) rate were calculated using the Kaplan-Meier method. LRC was defined from the first day of treatment until the first locoregional recurrence. OS was defined as the time between the first day of treatment and date of death from any cause or the last known date the patient was alive. The log-rank test was used to assess the correlation of survival end points with MTV and SUV max from 18 F-FDG PET/CT and other clinicopathologic factors. The Cox proportional hazard model was used for multivariate comparisons, and the estimated hazard ratio (HR) and 95% confidence interval (CI) were calculated. A two-sided P-value ≤0.05 was considered statistically significant. The sensitivity and specificity was stand on the cut-off value of MTV. All statistical analyses were performed using SPSS version 19.0 (SPSS Inc., Chicago, IL).
results
At the final follow-up, 62 patients were alive and 19 had died: 16 from laryngohypopharyngeal cancer, 2 from intercurrent complications (RT-induced pneumonia and acute renal failure), and 1 from a second primary cancer. The median follow-up for surviving patients was 40.4 months (range 24.5-90.1). The 3-year LRC and OS for all patients were 70.9 and 78.7%, respectively.
measurement of MTV cut-off value
The median SUV max was 10.3 (range 2.5-48.1) and the median MTV was 15.0 ml (range 0.1-85.7 ml). A receiver operating characteristic (ROC) curve was estimated for the calculation of the ideal MTV cut-off point with the OS as the gold standard ( Figure 2 ). Various MTV cut-off points were used to obtain the maximal sum of sensitivity and specificity. As a result, a cut-off of 18 ml was determined to be significant for MTV, with a original articles Annals of Oncology sensitivity of 76.4% and a specificity of 67.3% (P < 0.001, 95% CI = 0.600-0.831). To validate the selected cut-off point by ROC curve, we performed dichotomization analysis of patient survival with various cut-off points. The MTV value of 18 ml showed the most significant difference for survival in the logrank test.
prediction of patient survival
We compared survival outcomes according to clinicopathologic variables and MTV by univariate and multivariate analyses (Tables 2 and 3) . By univariate analysis, the patients with MTV > 18 ml had a significantly lower LRC (50.8% versus 85.3%, P < 0.001) and OS (61.6% versus 91.4%, P = 0.004) rates than patients with MTV ≤ 18 ml. Primary site and treatment strategy also correlated significantly with both LRC (P < 0.005) and OS (P < 0.05). SUV max showed a borderline correlation with OS (P = 0.068) but not LRC (P = 0.122).
By multivariate analysis, we found that MTV was an independent prognostic factor for both LRC (P = 0.018; HR = 3.141, 95% CI = 1.175-8.399) and OS (P = 0.008; HR = 3.758, 95% CI = 1.415-9.982). The primary tumor site was identified as a significant prognostic factor for LRC (P = 0.047; HR = 2.506, 95% CI = 1.012-6.209). The Kaplan-Meier curves for LRC and OS for patients with MTV > 18 ml and MTV ≤ 18 ml are presented in Figure 3 .
discussion
In advanced laryngeal and hypopharyngeal cancer, vocal cord fixation, cartilage invasion, and extralaryngeal spread are the main determinants for deciding on staging and treatment modality. However, it is difficult to determine exactly these invasion measures using the current imaging tools: CT imaging has limitations in determining cartilage invasion or extralaryngeal spread in advanced laryngeal cancer [16] [17] [18] [19] . MRI is deemed to be more precise in detecting cartilage invasion but peritumor inflammation can lead to overstaging, resulting in poor specificity and predictive value [19] [20] [21] . These limitations explain why preoperative and postoperative T staging often give different results. Because of the limitations of imaging tools and the inherent inadequacies of TNM staging in locoregionally advanced laryngohypopharyngeal cancer, tumor biology and tumor bulk instead of tumor stage might be more important in selecting treatment course and in tumor outcome [17] [18] [19] .
MTV, an unverified parameter for 18 F-FDG PET/CT, involves measuring the volume of tumors that take up a certain amount of 18 F-FDG. Because 18 F-FDG uptake correlates with cellular proliferation [22] [23] [24] and tumor behavior [25, 26] , it is likely that MTV reflects not only tumor bulk but also tumor biology. Research on the value of MTV in patients with HNSCC is lacking [14, 15, 27, 28] . These previous studies all concluded that MTV is a much better predictor of survival compared with SUV max . Seol et al. [14] studied 59 patients treated for locally advanced head and neck cancer and found that high MTV, but not SUV max , was associated with increased progressionfree survival and OS. Chung et al. [15] also showed that MTV, but not SUV max , can predict short-term outcome and 2-year disease-free survival in 82 pharyngeal cancer patients. The present study also showed that MTV could be a powerful prognostic factor in patients with advanced laryngeal and hypopharyngeal cancers. Patients with MTV > 18 ml were at more than three-fold higher risk of both locoregional recurrence and death than those with MTV ≤ 18 ml.
The pretreatment SUV max of 18 F-FDG PET/CT, a classic parameter for prognosis of head and neck cancer, was investigated in previous studies, many of which showed a worse clinical course with higher SUV max than did with lower SUV max [5, 29, 30] . These prior studies, however, involved HNSCCs stages, from early to advanced. In our previous study [31] , SUV values correlated significantly with 3-year disease-free survival but not with 3-year LRC. In the present study, in common with MTV, we used a ROC curve for calculation of the ideal cut-off point of SUV max . However, the association between SUV max and OS in our cohort was only of borderline significance. In our view, these results may be due to the fact that the study population was composed of only stage III and IV locoregionally advanced squamous cell carcinoma of larynx and hypopharynx patients. There may be controversy regarding the correlation between prognosis and SUV max , but the important point is that of the 18 F-FDG PET/CT parameters, MTV is a better predictor of prognosis and other studies support this [14, 15, 27, 28] .
Both primary site and treatment strategy were significantly correlated with LRC and OS by univariate analyses. The present study showed that the prognosis for advanced Figure 2 . Receiver operating characteristic curve analysis of survival prediction according to metabolic tumor volume in the 81 patients (continuous variable). Area under the curve was 0.718 (P < 0.001, 95% CI = 0.600-0.831), and 18 ml was determined as the metabolic tumor volume cut-off value for comparison. Sensitivity and specificity of the dichotomized metabolic tumor volume (≤18 versus >18) were 76.4% and 67.3%, respectively.
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laryngeal cancer is better than that of advanced hypopharyngeal cancer, and treatment results of RT and surgery are similar for both cancers. In our study, 43 out of 57 larynx cancer patients received surgery (75.4%) and 14 underwent RT or CRT. In contrast, out of 24 hypopharynx cancer patients, only 14 (24.6%) received surgery while 20 (83.3%) were treated with RT or CRT, which reveals a significant difference in treatment modality according to the primary site (P = 0.010, Fisher's exact test). The results indicate that the primary treatment strategy was highly influenced by the primary site, and by multivariate analysis, the primary site alone showed a significant correlation with LRC (P = 0.047).
The HNSCCs are histologically identical but clinically heterogeneous entities that show a disparity in natural course or clinical behavior based on primary location. Previous studies of MTV involved the entire head and neck and all stages of cancer, leading to a potential bias due to original articles Annals of Oncology tumor location or stage. The strength of this study is that we only included advanced squamous cell carcinoma of larynx and hypopharynx. Limitations were the different treatment modalities used (owing to the retrospective nature of the study) and the small number of cases.
In conclusion, pretreatment MTV of tumor represents an independent prognostic factor in patients with locoregionally advanced squamous cell carcinoma of the larynx and hypopharynx. Patients with high MTV > 18 ml have a poor survival outcome. The present study needs to be validated by large-scale prospective trials. Further studies focusing on prediction of occult metastasis, response to induction chemotherapy, and feasibility as a prognostic factor are required. 
